Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, Valabrega G. Tuninetti V, et al. Eur J Cancer. 2024 Mar 30;203:114039. doi: 10.1016/j.ejca.2024.114039. Online ahead of print. Eur J Cancer. 2024. PMID: 38598922
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: tuninetti v. Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023. Front Oncol. 2024. PMID: 38318323 Free PMC article.
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, Malaguti P, Baldoni A, Scollo P, Scandurra G, Parisi A, Artioli G, Palaia I, Vertechy L, Bergamini A, Picardo E, Tuninetti V, Scotto G, Scambia G, Pignata S, Valabrega G. Turinetto M, et al. Among authors: tuninetti v. Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041. Cancers (Basel). 2023. PMID: 38201470 Free PMC article.
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: tuninetti v. Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023. Front Oncol. 2023. PMID: 37781174 Free PMC article.
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Tuninetti V, Pace L, Ghisoni E, Quarà V, Arezzo F, Palicelli A, Mandato VD, Geuna E, Cormio G, Biglia N, Borsotti L, Gallo S, Ferrero A, Jacomuzzi E, Fuso L, Pezua Sanjinez JOS, Puppo A, Caglio A, Rognone C, Turinetto M, Scotto G, Di Maio M, Valabrega G. Tuninetti V, et al. Cancers (Basel). 2023 Jul 15;15(14):3639. doi: 10.3390/cancers15143639. Cancers (Basel). 2023. PMID: 37509300 Free PMC article.
Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report.
Zumstein L, Tuninetti V, Vaira M, Siatis D, Palermo F, Petracchini M, Scotto G, Turinetto M, Piva R, Pasini B, Valabrega G. Zumstein L, et al. Among authors: tuninetti v. Gynecol Oncol Rep. 2023 Jun 16;48:101220. doi: 10.1016/j.gore.2023.101220. eCollection 2023 Aug. Gynecol Oncol Rep. 2023. PMID: 37434947 Free PMC article.
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.
Rossi A, Aimar G, Audisio M, Bungaro M, Caglio A, Di Liello R, Gamba T, Gargiulo P, Ghisoni E, Lombardi P, Marandino L, Mariniello A, Paratore C, Reale ML, Trastu F, Tuninetti V, Turco F, Fabi A, Perrone F, Di Maio M. Rossi A, et al. Among authors: tuninetti v. Eur J Cancer. 2023 Aug;189:112920. doi: 10.1016/j.ejca.2023.05.008. Epub 2023 May 15. Eur J Cancer. 2023. PMID: 37277262
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Musacchio L, Turinetto M, Arenare L, Bartoletti M, Califano D, Tuninetti V, Marchetti C, Cormio G, Loizzi V, Pisano C, Salutari V, Valabrega G, Priolo D, Cecere SC, Ventriglia J, Raspagliesi F, Perrone F, Fagotti A, Lorusso D, Scambia G, Pignata S. Musacchio L, et al. Among authors: tuninetti v. Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23. Gynecol Oncol. 2023. PMID: 36965291
36 results